摘要
HBV感染是慢性乙型肝炎、肝硬化及肝细胞癌的主要致病因素。HBV共价闭合环状DNA(cccDNA)是HBV复制的模板,能长期稳定存在于肝细胞内,是病毒持续感染的主要因素。核苷(酸)类药物和干扰素等现有的抗病毒药物均不直接靶向cccDNA,故均难以实现慢性乙型肝炎临床治愈。随着生物技术的进步和对HBV cccDNA特性的深入了解,以靶向清除cccDNA为目标的抗病毒治疗研发日益增多,但离临床应用尚有较远的距离。简要综述了HBV cccDNA靶向药物及生物技术相关的研究进展。
Hepatitis B virus(HBV) infection is the main cause of chronic hepatitis B(CHB),liver cirrhosis,and hepatocellular carcinoma.HBV covalently closed circular DNA(cccDNA) is the template for HBV replication and exists stably in hepatocytes,which is the main factor for persistent infection.However,existing antiviral drugs including nucleos(t) ide analogues and interferons do not directly target cccDNA,and thus it is difficult to achieve the clinical cure of CHB.With the progress in biotechnology and in-depth understanding of the features of HBV cccDNA,more and more studies have been conducted on antiviral therapies targeting cccDNA,but there is still a long way before clinical application.This article briefly reviews related research advances.
作者
陈然
王杰
鲁凤民
CHEN Ran;WANG Jie;LU Fengmin(Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China)
出处
《临床肝胆病杂志》
CAS
北大核心
2019年第6期1188-1191,共4页
Journal of Clinical Hepatology
基金
国家“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项“十三五”计划(2017ZX10202202,2017ZX10202203)
北京市自然科学基金(7182080)
